Abbott (NYSE:ABT) filed three patent lawsuits against SiBionics and its distribution partner in Europe, JUVE-Patent reports.
The lawsuits include patent infringement allegations centered around continuous glucose monitoring (CGM) devices, according to the report. Abbott filed them against China-based SiBionics and its sales partner Umedwings at the Unified Patent Court.
SiBionics develops, manufactures and distributes CGM and other monitoring technologies. It received CE mark approval for its GS1 continuous glucose monitoring (CGM) system last fall. Umedwings, a Dutch company, serves as its distribution partner in Europe.
Get the full story at our sister site, Drug Delivery Business News.